IM Olanzapine Versus Haloperidol or Midazolam
Primary Purpose
Acute Agitation, Behavioural Emergency
Status
Terminated
Phase
Phase 4
Locations
Hong Kong
Study Type
Interventional
Intervention
Olanzapine
Haloperidol
Midazolam
Sponsored by
About this trial
This is an interventional treatment trial for Acute Agitation, Behavioural Emergency focused on measuring emergency, emergency medicine, sedation, acute agitation
Eligibility Criteria
Inclusion Criteria:
- Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
Exclusion Criteria:
Patients will be excluded if there are
- known hypersensitivity or contraindication to the study drugs
- reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)
- known pregnancy
- acute alcohol withdrawal
- patients aged>75 years.
Sites / Locations
- Pamela Youde Nethersole Eastern Hospital
- Prince of Wales Hospital
- Queen Mary Hospital
- Ruttonjee Hospital
- Tuen Mun Hospital
- United Christian Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Olanzapine
Haloperidol
Midazolam
Arm Description
intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
Outcomes
Primary Outcome Measures
Time to achieve adequate sedation
Adequate sedation is determined by a 6-point validated scale.
Secondary Outcome Measures
Total study drug doses administered; alternative drugs and doses used
Prolonged QTc interval
AED length of stay (LOS)
Adverse events
including airway management (jaw thrust, oral, nasal airway), need for assisted ventilation (bag/mask, intubation), oxygen desaturation <90%, systolic BP<90 mmHg, dystonic reactions, seizures, vomiting or aspiration
Full Information
NCT ID
NCT02380118
First Posted
January 29, 2015
Last Updated
November 3, 2022
Sponsor
The University of Hong Kong
Collaborators
Queen Mary Hospital, Hong Kong, Tuen Mun Hospital, Pamela Youde Nethersole Eastern Hospital, Ruttonjee Hospital, Prince of Wales Hospital, Shatin, Hong Kong, United Christian Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02380118
Brief Title
IM Olanzapine Versus Haloperidol or Midazolam
Official Title
Intramuscular Olanzapine Versus Haloperidol or Midazolam for the Management of Acute Agitation in the Emergency Department - a Multicentre Randomised Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Terminated
Why Stopped
Primary endpoint reached based on data projection from interim analysis.
Study Start Date
December 2014 (Actual)
Primary Completion Date
September 2019 (Actual)
Study Completion Date
September 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong
Collaborators
Queen Mary Hospital, Hong Kong, Tuen Mun Hospital, Pamela Youde Nethersole Eastern Hospital, Ruttonjee Hospital, Prince of Wales Hospital, Shatin, Hong Kong, United Christian Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether intramuscular olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or midazolam when used in the management of acute agitation in the emergency department.
Detailed Description
To address significant knowledge gaps by several means:
Investigate intramuscular use of sedative drugs within a predominantly Chinese population, to address this void in international literature impacting the management of acute agitation.
The multi-centre RCT will determine the safety and efficacy of intramuscular olanzapine, in comparison with conventional medicines (haloperidol or midazolam) in a three-arm comparison for the sedation of acutely agitated patients in emergency department. Specifically, we aim to determine if administration of intramuscular olanzapine (a)is more effective than sedation with intramuscular haloperidol or intramuscular midazolam alone; (b)is safer than sedation with comparison arms; (c)decreases the amount of subsequent redosing or alternative drugs required; (d)is more favourable than the haloperidol and midazolam arms with respect to safety, efficacy and adverse events.
Investigate potential variables leading to emergency attendance and/or admission requiring parenteral sedation. These may include patient demographics and regular medications and adherence.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Agitation, Behavioural Emergency
Keywords
emergency, emergency medicine, sedation, acute agitation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
167 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Olanzapine
Arm Type
Experimental
Arm Description
intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
Arm Title
Haloperidol
Arm Type
Active Comparator
Arm Description
intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
Arm Title
Midazolam
Arm Type
Active Comparator
Arm Description
intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Other Intervention Name(s)
ZYPREXA
Intervention Description
Intramuscular injection
Intervention Type
Drug
Intervention Name(s)
Haloperidol
Intervention Description
Intramuscular injection
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
Intramuscular injection
Primary Outcome Measure Information:
Title
Time to achieve adequate sedation
Description
Adequate sedation is determined by a 6-point validated scale.
Time Frame
Within 60 minutes from drug administration
Secondary Outcome Measure Information:
Title
Total study drug doses administered; alternative drugs and doses used
Time Frame
From Emergency Department admission to transfer or discharge from AED, an expected average of 1 hour
Title
Prolonged QTc interval
Time Frame
From Emergency Department admission to transfer or discharge from Emergency Department, an expected average of 1 hour
Title
AED length of stay (LOS)
Time Frame
From Emergency Department admission to transfer or discharge from Emergency Department, an expected average of 1 hour
Title
Adverse events
Description
including airway management (jaw thrust, oral, nasal airway), need for assisted ventilation (bag/mask, intubation), oxygen desaturation <90%, systolic BP<90 mmHg, dystonic reactions, seizures, vomiting or aspiration
Time Frame
From Emergency Department admission to transfer or discharge from Emergency Department an expected average of 1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
Exclusion Criteria:
Patients will be excluded if there are
known hypersensitivity or contraindication to the study drugs
reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)
known pregnancy
acute alcohol withdrawal
patients aged>75 years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Esther WY Chan, PhD
Organizational Affiliation
The University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pamela Youde Nethersole Eastern Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Prince of Wales Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Ruttonjee Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
Tuen Mun Hospital
City
Hong Kong
Country
Hong Kong
Facility Name
United Christian Hospital
City
Hong Kong
Country
Hong Kong
12. IPD Sharing Statement
Citations:
PubMed Identifier
16091097
Citation
Knott JC, Bennett D, Rawet J, Taylor DM. Epidemiology of unarmed threats in the emergency department. Emerg Med Australas. 2005 Aug;17(4):351-8. doi: 10.1111/j.1742-6723.2005.00756.x.
Results Reference
background
PubMed Identifier
22981685
Citation
Chan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong DC. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2013 Jan;61(1):72-81. doi: 10.1016/j.annemergmed.2012.07.118. Epub 2012 Sep 13.
Results Reference
background
PubMed Identifier
16387219
Citation
Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med. 2006 Jan;47(1):61-7. doi: 10.1016/j.annemergmed.2005.07.003. Epub 2005 Aug 18.
Results Reference
background
PubMed Identifier
21091874
Citation
Chan EW, Taylor DM, Knott JC, Kong DC. Variation in the management of hypothetical cases of acute agitation in Australasian emergency departments. Emerg Med Australas. 2011 Feb;23(1):23-32. doi: 10.1111/j.1742-6723.2010.01348.x. Epub 2010 Nov 22.
Results Reference
background
PubMed Identifier
19527287
Citation
Chan EW, Knott JC, Taylor DM, Phillips GA, Kong DC. Intravenous olanzapine--another option for the acutely agitated patient? Emerg Med Australas. 2009 Jun;21(3):241-2. doi: 10.1111/j.1742-6723.2009.01190.x. No abstract available.
Results Reference
background
PubMed Identifier
23186399
Citation
Chan EW, Taylor DM, Knott JC, Liew D, Kong DC. The pharmacoeconomics of managing acute agitation in the emergency department: what do we know and how do we approach it? Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):589-95. doi: 10.1586/erp.12.53.
Results Reference
background
PubMed Identifier
33681744
Citation
Chan EW, Lao KSJ, Lam L, Tsui SH, Lui CT, Wong CP, Graham CA, Cheng CH, Chung TS, Lam HF, Ting SM, Knott JC, Taylor DM, Kong DCM, Leung LP, Wong ICK. Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial. EClinicalMedicine. 2021 Feb 11;32:100751. doi: 10.1016/j.eclinm.2021.100751. eCollection 2021 Feb.
Results Reference
derived
Learn more about this trial
IM Olanzapine Versus Haloperidol or Midazolam
We'll reach out to this number within 24 hrs